chronic
hepat
b
viru
hbv
infect
associ
high
risk
develop
liver
cirrhosi
hepatocellular
carcinoma
hcc
thu
still
one
major
problem
threaten
human
health
global
major
challeng
antihbv
therapi
overcom
low
efficaci
high
rate
drug
resist
advers
effect
current
avail
drug
henc
urgent
need
develop
new
therapeut
strategi
one
potenti
strategi
rna
interfer
rnai
gene
silenc
regulatori
mechan
present
virtual
eukaryot
employ
doublestrand
rna
molecul
degrad
function
inactiv
target
rna
sequencespecif
manner
numer
studi
shown
replic
variou
virus
includ
hcv
sarsassoci
coronaviru
well
hbv
suppress
rnai
use
synthet
sirna
plasmidbas
shrna
howev
due
short
halflif
low
transfect
effici
clinic
applic
limit
regard
nonrepl
recombin
viral
vector
high
deliveri
effici
may
provid
novel
antivir
option
lv
intens
optim
last
decad
one
promis
system
provid
nonpathogen
latent
infect
integr
host
genom
also
demonstr
high
transduct
effici
divid
nondivid
cell
persist
transgen
express
current
lvbase
vaccin
alreadi
test
preclin
trial
protect
treatment
moreov
sever
rout
lv
administr
invok
sustain
antihiv
immun
respons
explor
mice
find
suggest
lv
may
also
suitabl
deliveri
vector
gene
therapi
antivir
treatment
addit
novel
tetracyclin
doxycyclin
dox
respect
regul
rnai
system
base
lv
develop
avoid
undesir
toxic
may
induc
longterm
shrna
express
system
fusion
protein
ttrkrab
dna
bind
domain
escherichia
coli
tetracyclin
repressor
ttr
approxim
amino
acid
krab
repressor
likewis
deliv
lv
lvttrkrab
krab
suppress
transcript
rna
polymeras
ii
rna
polymeras
iii
promot
within
distanc
kb
bind
site
mechan
entir
known
seem
involv
local
heterochromatin
format
histon
deacetyl
andor
indirect
influenc
arrang
basal
transcript
machineri
promot
juxtapos
tet
oper
teto
sequenc
lvhbvshrna
vector
use
studi
ttrkrab
protein
specif
target
promot
ttr
domain
repress
shrna
transcript
absenc
dox
convers
addit
dox
releas
ttrkrab
teto
thu
permit
shrna
express
fig
studi
construct
lvhbvshrna
vector
target
three
function
import
therefor
highli
conserv
region
hbv
genom
fig
name
target
site
nt
posit
core
promot
cp
target
site
nt
posit
rt
domain
encod
region
polymeras
gene
target
site
nt
posit
essenti
cisel
replic
copi
pregenom
pg
rna
contain
acceptor
site
dna
primer
gener
initi
revers
transcript
cp
control
transcript
pgrna
serv
templat
hbv
dna
synthesi
also
mrna
polymeras
core
protein
precor
rna
precor
protein
precursor
secret
hbeag
translat
moreov
cp
region
overlap
cisel
facilit
firststrand
templat
switch
initi
minusstrand
dna
synthesi
rt
region
hbv
polymeras
essenti
revers
transcriptas
activ
top
nucleotid
sequenc
overlappingli
encod
part
gene
least
suitabl
rnai
target
specif
rt
region
chosen
alreadi
demonstr
use
simpl
shrna
express
plasmid
therefor
explor
feasibl
exploit
lv
effici
deliveri
shrna
cp
rt
region
assess
antivir
efficaci
stabli
hbvtransfect
human
hepatoma
cell
line
subsequ
shrna
exert
strongest
interfer
select
evalu
antivir
efficaci
doxcontrol
system
shown
antivir
activ
strictli
doxdepend
allow
profoundli
affect
hbv
gene
express
replic
regul
fashion
vector
psuper
contain
human
promot
use
backbon
gener
seri
shrna
express
plasmid
insert
follow
anneal
oligonucleotid
actual
target
sequenc
sens
oligonucleotid
underlin
hindiii
bglii
site
target
rt
region
nt
posit
ccc
cgc
tca
gtt
tac
tag
tgc
ctt
tca
aga
gat
ggc
act
agt
aaa
ctg
agc
ttt
sens
cga
gtc
aaa
tga
tca
cgg
aaa
gtt
ctc
tac
cgt
gat
cat
ttg
act
cga
aaa
att
antisens
target
cp
region
nt
posit
ccc
cct
agg
agg
ctg
tag
gca
taa
att
caa
gag
att
tat
gcc
tac
agc
ctc
cta
gtt
ttt
sens
gat
cct
ccg
aca
tcc
gta
ttt
aag
ttc
tct
aaa
tac
gga
tgt
cgg
agg
atc
aaa
aat
tcg
antisens
target
nt
ccc
ctt
cac
ctc
tgc
cta
atc
att
tca
aga
gaa
tga
tta
ggc
aga
ggt
gaa
ttt
sens
aag
tgg
aga
cgg
att
agt
aaa
gtt
ctc
tta
cta
atc
cgt
ctc
cac
tta
aaa
att
antisens
target
viral
transcript
target
transcript
except
hbx
mrna
fig
shrna
target
pgrna
serv
templat
hbv
genom
replic
well
mrna
core
antigen
polymeras
moreov
also
target
hbv
hbsag
mrna
target
hbsag
mrna
hbx
mrna
fig
neg
control
oligonucleotid
agt
gaa
ggg
cgt
atg
att
att
caa
gag
ata
atc
ata
cgc
cct
tca
cta
gtt
sens
gat
cac
ttc
ccg
cat
act
aat
aag
ttc
tct
att
agt
atg
cgg
gaa
gtg
atc
aaa
aat
tcg
antisens
employ
construct
analog
psuper
vector
psupershrnanc
encod
shrna
lack
perfect
match
hbv
cellular
sequenc
shrna
target
sequenc
blast
search
human
genom
plu
transcript
databas
ncbi
exclud
excess
similar
human
gene
mrna
sequenc
shrna
express
cassett
includ
promot
plasmid
verifi
dna
sequenc
lentivir
plvhbvshrna
express
vector
construct
insert
bp
ecori
clai
fragment
contain
promot
plu
shrna
sequenc
respect
psuperhbvshrna
plasmid
plvth
also
encod
green
fluoresc
protein
gfp
facilit
determin
viral
titer
construct
confirm
restrict
endonucleas
analysi
recombin
lentivirus
lvhbvshrna
lvttrkrab
gener
cell
mm
plate
transient
transfect
three
plasmid
lipofectaminetm
invitrogen
carlsbad
us
brief
produc
lvhbvshrna
cell
cotransfect
plvhbvshrna
express
gagpol
tet
rev
gene
requir
effici
lentiviru
product
express
vsv
envelop
glycoprotein
g
lvttrkrab
produc
analog
plvttrkrab
lv
particl
harvest
h
later
centrifug
remov
cell
debri
min
filter
cellulos
acet
filter
millipor
concentr
ultrahigh
speed
centrifug
g
h
viru
stock
store
use
infecti
titer
determin
transduct
cell
known
amount
stock
solut
tenfold
dilut
correspond
per
ml
medium
one
well
plate
seed
cell
count
gfpposit
cell
typic
titer
around
transduc
unitsml
cell
cultur
dulbecco
modifi
eagl
medium
dmem
gibco
life
technolog
supplement
fetal
bovin
serum
fb
gibco
human
hepatoblastoma
cell
line
stabli
transfect
headtotail
dimer
hbv
dna
cultur
dmem
supplement
fb
ngml
gibco
cell
cultur
maintain
moist
atmospher
contain
transduct
lvhbvshrna
vector
cell
carri
use
polybren
sigmaaldrich
brief
cell
seed
densiti
cell
per
well
plate
h
cell
inocul
lvhbvshrna
vector
particl
multipl
infect
moi
presenc
polybren
overnight
incub
cultur
medium
replac
fresh
complet
medium
transduct
effici
routin
indic
fraction
gfpposit
cell
effect
lvhbvshrna
secret
hbsag
hbeag
assess
h
week
transduct
lvhbvshrna
vector
use
enzymelink
immunosorb
assay
elisa
kit
follow
manufactur
instruct
kehua
co
shanghai
china
quantifi
hbv
mrna
introduc
lvhbvshrna
cell
line
total
rna
extract
transduc
cell
h
posttransduct
use
trizol
reagent
invitrogen
usa
reversetranscrib
rt
use
oligo
dt
prime
quantit
realtim
pcr
carri
use
sybrgreen
pcr
master
mix
chemistri
toyobo
japan
follow
manufactur
instruct
valu
normal
mrna
intern
control
primer
sequenc
tgt
tac
agg
cgg
ggt
forward
tgc
gaa
ttt
tgg
cca
revers
hbv
region
cgg
tga
agg
tga
forward
aga
gaa
gtg
ggg
revers
reaction
run
duplic
use
stratagen
qpcr
system
agil
technolog
level
encapsid
hbv
replic
dna
intermedi
assess
southern
blot
encapsid
hbv
dna
purifi
use
method
describ
guo
et
al
brief
cell
wash
icecold
phosphatebuff
salin
pb
lyse
lysi
buffer
mm
trishcl
mm
edta
per
well
cell
lysat
place
ice
min
centrifug
min
supernat
adjust
mm
treat
dnase
rnase
min
reaction
stop
addit
edta
protein
digest
mgml
proteinas
k
presenc
sodium
dodecyl
sulfat
h
nucleic
acid
purifi
extract
ethanol
precipit
dissolv
hbv
dna
isol
intracellular
core
particl
separ
agaros
gel
blot
onto
nylon
membran
hybrid
unitlength
hbv
dna
fragment
band
visual
phosphorimag
cyclon
plu
perkin
elmer
exam
viral
load
cultur
supernat
hbv
dna
extract
use
tianamp
viru
dnarna
kit
tiangen
biotech
co
beij
china
quantifi
realtim
polymeras
chain
reaction
use
sybrgreen
pcr
master
mix
chemistri
toyobo
japan
primer
sequenc
follow
tgc
caa
ctg
gat
cct
gcg
forward
acg
gtg
gtc
tcc
atg
revers
amplif
perform
min
min
total
cycl
follow
min
total
hbv
dna
follow
min
signal
collect
level
express
hbv
gene
measur
use
threshold
cycl
c
c
threshold
cycl
hbv
core
protein
detect
immunoblot
use
antihbcag
mous
monoclon
antibodi
brief
treat
cell
wash
twice
icecold
pb
lyse
lysi
buffer
mm
trishcl
ph
mm
nacl
sd
deoxychol
acid
sodium
azid
pmsf
per
well
plate
total
protein
sampl
load
sdspage
subsequ
gel
electroblot
pvdf
membran
soak
min
block
solut
incub
h
room
temperatur
mous
monoclon
antihbcag
antibodi
dilut
kindli
provid
dr
nassal
univers
hospit
freiburg
germani
intern
control
housekeep
protein
gapdh
blot
detect
use
mous
antigapdh
monoclon
antibodi
dilut
invitrogen
three
wash
blot
incub
appropri
peroxidas
conjug
secondari
antibodi
band
visual
use
dab
western
blot
kit
thermo
cell
seed
plate
densiti
cell
per
well
transduc
h
later
lvttrkrab
vector
particl
ratio
presenc
polybren
incub
transduc
cell
split
two
equal
aliquot
one
aliquot
maintain
absenc
presenc
dox
week
monitor
potenti
direct
impact
dox
shrna
express
lvhbvshrna
absenc
ttrkrab
parent
cell
cell
transduc
naiv
cell
also
cultur
week
presenc
dox
analyz
parallel
hbv
gene
express
replic
describ
experi
perform
three
time
independ
data
express
documentclass
minim
usepackag
amsmath
usepackag
wasysym
usepackag
amsfont
usepackag
amssymb
usepackag
amsbsi
usepackag
mathrsf
usepackag
upgreek
setlength
oddsidemargin
begin
document
overlin
text
x
end
document
standard
deviat
sd
comparison
group
perform
independentsampl
test
level
signific
set
p
initi
test
function
shrna
cell
transfect
psuperhbvshrna
plasmid
neg
control
vector
psupershrnanc
untreat
cell
serv
refer
hbsag
hbeag
supernat
h
determin
elisa
shown
supplementari
fig
achiev
strongest
reduct
follow
signific
differ
cell
receiv
neg
control
plasmid
untransfect
cell
seen
hbsag
level
maxim
reduc
hbeag
level
data
confirm
hbvspecif
shrna
act
intend
higher
level
inhibit
would
expect
cell
contain
integr
hbv
fraction
transfect
shrna
plasmid
next
analog
experi
perform
lvhbvshrna
vector
transduc
cell
except
observ
period
extend
week
hbvshrna
express
lv
led
signific
p
reduct
hbsag
fig
hbeag
fig
compar
untreat
control
shrna
vector
transduc
cell
antivir
effect
slightli
increas
h
h
posttransduct
remain
similar
level
entir
observ
period
psuperhbvshrna
transfect
cell
exert
strongest
effect
howev
level
inhibit
much
pronounc
especi
hbsag
achiev
around
inhibit
around
around
hbeag
suppress
gener
less
effici
maximum
inhibit
rate
reason
lower
impact
hbeag
clear
similar
observ
also
report
other
neg
control
shrna
vector
exhibit
suppress
effect
hbsag
hbeag
level
compar
untreat
cell
corrobor
neither
shrna
lv
neg
impact
cell
demonstr
hbv
specif
shrna
one
week
posttransduct
total
rna
extract
cell
analyz
realtim
rtpcr
use
hbvspecif
specif
primer
rel
ratio
hbv
specif
signal
compar
untreat
cell
shown
fig
consist
elisa
data
caus
massiv
close
reduct
hbv
rna
follow
around
also
assay
hbv
rna
remain
unaffect
nonspecif
shrna
encod
neg
control
vector
level
hbv
dna
extracellular
particl
assess
realtim
pcr
intracellular
nucleocapsid
southern
blot
shown
fig
target
decreas
extracellular
viral
load
week
posttransduct
compar
untreat
neg
control
shrna
vector
transduc
cell
inhibit
compar
half
strong
pronounc
inhibit
hbv
replic
hbv
transcript
protein
express
also
previous
observ
antihbv
shrna
might
reflect
effect
beyond
rna
degrad
overal
consist
data
obtain
southern
blot
analysi
hbv
dna
associ
intracellular
nucleocapsid
fig
almost
replic
dna
intermedi
found
transduc
cell
higher
level
seen
transduc
cell
still
reduc
compar
untreat
control
lvshrna
transduc
cell
anoth
paramet
antivir
activ
monitor
hbv
core
protein
express
western
blot
fig
show
signific
reduct
core
protein
level
compar
gapdh
transduc
cell
togeth
data
show
transduct
induc
strongest
antivir
effect
base
data
report
chose
employ
vector
investig
feasibl
use
doxinduc
rnai
system
control
express
antihbv
shrna
thu
also
hbv
gene
express
replic
regul
manner
end
cell
subject
variou
treatment
one
group
transduc
refer
second
plu
lvttrkrab
inhibit
express
antihbv
shrna
third
group
receiv
addit
dox
reliev
ttrkrab
mediat
suppress
rnai
monitor
potenti
direct
ttrkrab
mediat
effect
dox
shrna
vector
fourth
group
transduc
cultur
dox
lastli
potenti
impact
dox
cell
hbv
replic
cell
address
cultur
naiv
cell
dox
contain
medium
test
secret
hbsag
hbeag
core
protein
viral
replic
dna
intermedi
intracellular
nucleocapsid
fulli
consist
previou
data
caus
strong
reduct
hbsag
less
pronounc
reduct
hbeag
fig
affect
presenc
dox
also
impact
naiv
cell
cotransduct
lvttrkrab
absenc
dox
complet
block
antivir
effect
give
similar
elisa
valu
untreat
cell
presenc
dox
howev
complet
restor
hbsag
hbeag
suppress
level
indistinguish
achiev
vector
alon
suppress
secret
antigen
presenc
dox
inhibit
suppress
absenc
larg
maintain
week
trend
toward
slightli
less
effici
hbsag
suppress
late
time
point
consist
result
obtain
transduct
lvhbvshrna
vector
fig
may
reflect
slow
select
cell
produc
less
shrna
compar
result
obtain
core
protein
express
fig
presenc
dox
cell
cotransduc
ttrkrab
vector
show
similarli
low
core
protein
level
cell
transduc
vector
wherea
without
dox
ttrkrab
vector
cotransduc
cell
still
contain
high
level
core
protein
final
result
confirm
nucleocapsidassoci
viral
dna
southern
blot
fig
alon
regardless
presenc
dox
plu
lvttrkrab
presenc
dox
caus
similarli
strong
reduct
wherea
omit
dox
cotransduct
experi
complet
block
antivir
effect
togeth
result
show
first
dox
act
specif
ttrkrab
intend
importantli
assay
confirm
complet
revers
ttrkrab
mediat
rnai
suppress
dox
henc
system
allow
deliber
turn
hbv
replic
cell
without
neg
effect
cell
numer
studi
explor
rnai
potenti
therapeut
option
inhibit
viral
replic
report
eg
hav
hcv
hsv
other
although
hbv
dna
viru
rna
play
key
role
replic
templat
gener
new
dna
genom
revers
transcript
therefor
rnai
act
viral
mrna
prevent
gener
viral
protein
directli
interfer
hbv
replic
confirm
sever
studi
employ
synthet
sirna
plasmidbas
shrna
target
differ
region
hbv
genom
vitro
hydrodynam
transfect
mice
vivo
howev
due
short
halflif
sirna
limit
variabl
transfect
effici
shrna
plasmid
inhibitori
effect
transient
last
day
limit
applic
longterm
gene
silenc
mammalian
system
issu
partial
overcom
use
adenoviru
retrovirusbas
vector
shrna
express
success
appli
suppress
hbv
replic
howev
adenovir
vector
integr
like
lost
cell
divis
thu
achiev
transient
shrna
express
furthermor
adenoviru
common
human
pathogen
vivo
deliveri
may
hamper
preexist
host
immun
respons
retrovirus
hand
requir
cell
divis
integr
henc
ineffici
transduc
gene
nondivid
cell
quiescent
hepatocyt
recent
develop
druginduc
lentivir
vector
shrna
deliveri
vehicl
offer
sever
advantag
compar
aforement
system
first
integr
host
genom
allow
stabl
persist
shrna
express
second
transduc
divid
nondivid
cell
high
effici
third
gene
silenc
regul
addit
dox
minim
potenti
toxic
induc
longterm
shrna
express
induct
interferon
respons
offtarget
activ
complementar
nontarget
gene
six
seven
nucleotid
guid
strand
far
induc
rnai
system
appli
differ
area
includ
regul
housekeep
gene
express
antivir
research
although
lentivirusmedi
rnai
suppress
hbv
replic
alreadi
report
current
studi
knowledg
first
establish
revers
effect
shrna
hbv
via
drugregul
lentivir
vector
system
first
result
demonstr
lvhbvshrna
express
antihbv
shrna
induc
effici
gene
silenc
vitro
consist
data
cell
transfect
parent
psuperhbvshrna
plasmid
supplementari
fig
lvdeliv
target
cp
region
especi
target
region
effici
direct
rt
region
suppress
hbsag
hbeag
fig
howev
level
inhibit
durat
silenc
effect
much
pronounc
lvdeliv
shrna
instanc
suppress
hbsag
product
hbsag
h
posttransduct
fig
highli
effici
suppress
maintain
week
fig
like
explan
transfect
reach
fraction
viru
produc
cell
nonrepl
plasmid
dilut
cell
divis
contrast
transduct
lv
highli
effici
around
experi
shrna
express
cassett
becom
stabli
integr
trend
toward
slightli
lower
suppress
week
may
reflect
slow
select
cell
reduc
shrna
express
overal
similar
result
observ
secret
hbeag
although
suppress
less
pronounc
hbsag
plasmidtransfect
lvtransduc
cell
fig
supplementari
fig
obviou
explan
similar
result
report
uprichard
et
al
deng
et
al
suggest
rel
rnai
resist
precor
mrna
compar
kb
mrna
may
due
global
protect
within
rnaprotein
complex
rough
endoplasm
reticulum
altern
explan
could
express
hbeag
cell
system
use
limit
mrna
level
efficaci
posttransl
step
protein
product
rate
rtpcr
assay
fig
demonstr
also
strong
reduct
level
hbv
rna
vector
particularli
vector
around
without
affect
housekeep
gene
mrna
caus
limit
suppress
hbv
rna
probabl
due
poor
target
access
affect
rna
structur
protein
bind
paramet
difficult
assess
high
activ
may
relat
fact
target
region
present
two
copi
pgrna
see
fig
rnai
target
either
site
would
induc
degrad
pgrna
prevent
act
templat
revers
transcript
result
consist
secret
antigen
rna
data
also
obtain
extracellular
fig
intracellular
fig
viral
dna
determin
qpcr
southern
blot
achiev
strong
sustain
inhibit
somewhat
surpris
still
strong
suppress
extracellular
hbv
dna
howev
overal
replic
vulner
rnai
express
individu
gene
product
previous
observ
antihbv
shrna
suggest
interfer
replic
may
exclus
occur
target
rna
degrad
involv
mechan
instanc
sequencespecif
bind
guid
rna
could
block
interact
site
pgrna
import
packag
revers
transcript
exert
highest
antivir
activ
employ
vector
investig
potenti
doxinduc
ttrkrab
system
achiev
regul
shrna
express
consequ
regul
hbv
gene
express
replic
control
confirm
dox
per
se
neither
affect
hbv
replic
naiv
cell
suppress
hbv
replic
cell
transduc
importantli
howev
cotransduc
lvttrkrab
complet
abrog
antivir
effect
absenc
dox
wherea
addit
dox
fulli
restor
antivir
activ
shown
secret
viral
antigen
fig
core
protein
express
fig
replic
fig
conclus
data
confirm
region
highli
effici
target
site
antihbv
rnai
superior
effici
shrna
deliveri
lentivir
vector
result
much
stronger
sustain
antivir
activ
moreov
demonstr
doxcontrol
system
allow
fulli
revers
regul
antivir
shrna
effect
thu
also
hbv
replic
stabli
hbv
express
human
hepatoma
cell
line
henc
new
system
provid
valuabl
platform
studi
pharmacokinet
rna
drug
gener
hbv
particular
data
also
suggest
potenti
system
therapeut
purpos
possibl
combin
convent
antihbv
drug
nucleo
ide
analog
priori
reduc
viral
load
howev
prior
practic
applic
treatment
chronic
hbv
infect
studi
anim
model
requir
evalu
effici
safeti
vivo
includ
potenti
toxic
ttrkrab
fusion
protein
